Drug-induced sarcoidosis-like reaction three months after BNT162b2 mRNA COVID-19 vaccination: A case report and review of literature

Table 1 Laboratory values and tumor markers

AST	34 U/L (7-38 IU/L)	HbA1c	6.3% (4.6%-6.2%)
ALT	15 U/L (4-44 IU/L)	HCV Ab	(+)
ALP	118 U/L (36-126 IU/mL)	HCV RNA	(-)
LDH	206 U/L (120-240 U/L)	HBs Ag	(-)
γ-GTP	104 U/L (< 40 IU/L)	HBs Ab	(-)
T-Bil	1.0 mg/dL (0.2-1.2 mg/dL)	HBc Ab	(-)
TP	9.0 g/dL (6.5-8.2 g/dL)	sIL-2R	937 U/mL (122-496 U/mL)
Alb	4.6 g/dL (3.9-4.9 g/dL)	Lysozyme	16.7 µg/mL (5.0-10.0 µg/mL)
AMY	126 U/L (38-136 U/L)	ACE	12.5 U/L (7.7-29.4 IU/L)
CRP	0.52 mg/dL (< 0.30 mg/dL)	IgG	2464 mg/dL (800-1750 mg/dL)
BUN	21.2 mg/dL (< 40 IU/L)	IgA	547 mg/dL (100-450 mg/dL)
Cre	1.28 mg/dL (0.61-1.04 mg/dL)	IgM	50 mg/dL (45-300 mg/dL)
WBC	5200/µL (3600-9000/µL)	ANA	(-)
RBC	325 × 104/µL [(410-530) × 104/µL]	AMA	(-)
Hb	10.6 g/dL (13-18 g/dL)	AFP	3.3 ng/mL (< 10.0 ng/mL)
Plt	17.2 × 104/µL [(12-30) × 104/µL]	PIVKA-II	26 mAU/mL (< 40 mAU/mL)
FBG	110 mg/dL (60-110 mg/dL)	CA19-9	26.8 U/mL (< 37.0 U/mL)
		CEA	1.4 ng/mL (< 5.0 ng/mL)

AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; LDH: Lactate dehydrogenase; γ-GTP: γ-glutamyl transpeptidase; T-Bil: Total bilirubin; TP: Total protein; Alb: Albumin; AMY: Amylase; CRP: C-reactive protein; BUN: Blood urea nitrogen; Cre: Creatinine; WBC: White blood cellt; RBC: Red blood cell; Hb: Hemoglobin; Plt: Platelet; FBG: Fasting blood glucose; HbA1c: Hemoglobin A1c; HCV Ab: Hepatitis C virus antibody; HCV RNA: Hepatitis C virus ribonucleic acid; HBs Ag: Hepatitis B virus S antigen; HBs Ab: Hepatitis B virus S antibody; HBc Ab: Hepatitis B virus C antibody; sIL-2R: Soluble interleukin-2 receptor; ACE: Angiotensin-converting enzyme; IgG: Immunoglobulin G; IgA: Immunoglobulin A; IgM: Immunoglobulin M; ANA: Antinuclear antibodies; AMA: Anti-mitochondrial antibody; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence or antagonist Ⅱ; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen.